Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma

Frontiers in Immunology

Immunology

Xiangsheng Fu¹  Feng He¹  Hui Huang¹  Ming Zhao¹ 

[1] Department of Gastroenterology, Clinical Medical College and the First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China;

关键词: hepatocellular carcinoma;    tumor microenvironment;    cancer immunotherapy;    immunocheck point inhibitors;    adoptive cell therapy;   

DOI  :  10.3389/fimmu.2023.1188277

 received in 2023-03-20, accepted in 2023-05-04,  发布年份 2023

来源: Frontiers

【 摘 要 】

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and shows high global incidence and mortality rates. The liver is an immune-tolerated organ with a specific immune microenvironment that causes traditional therapeutic approaches to HCC, such as chemotherapy, radiotherapy, and molecular targeted therapy, to have limited efficacy. The dramatic advances in immuno-oncology in the past few decades have modified the paradigm of cancer therapy, ushering in the era of immunotherapy. Currently, despite the rapid integration of cancer immunotherapy into clinical practice, some patients still show no response to treatment. Therefore, a rational approach is to target the tumor microenvironment when developing the next generation of immunotherapy. This review aims to provide insights into the hepatic immune microenvironment in HCC and summarize the mechanisms of action and clinical usage of immunotherapeutic options for HCC, including immune checkpoint blockade, adoptive therapy, cytokine therapy, vaccine therapy, and oncolytic virus-based therapy.

【 授权许可】

Unknown   
Copyright © 2023 Zhao, Huang, He and Fu